A Phase III, Multicenter, Randomized, Double-blind Clinical Trail to Assess JMT103 Compared to Azoledronic Acid for the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Narlumosbart (Primary) ; Zoledronic acid
- Indications Bone disorders; Bone metastases
- Focus Adverse reactions; Registrational
- Sponsors Shanghai JMT-BIO Technology
Most Recent Events
- 29 Jan 2024 New trial record